Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

matory cytokines in cancer. J Clin Invest
1993; 91: 1005±10.
96 Filgueira L, Zuber M, Merlo A, et al.
Cytokine gene transcription in renal
cell carcinoma. Br J Surg 1993; 80:
1322±5.
97 Asadullah K, Docke WD, Haeussler
A, Sterry W,Volk HD. Progression of
mycosis fungoides is associated with increasing
cutaneous expression of interleukin-10
mRNA. J Invest Dermatol
1996; 107: 833±7.
98 Asadullah K, Gellrich S, Haeussler-
Quade A, et al. Cytokine expression in
primary cutaneous germinal center cell
lymphomas. Exp Dermatol 2000; 9: 71±
6.
99 Filella X, Alcover J, Zarco MA,
Beardo P, Molina R, Ballesta AM.
Analysis of type T1 and T2 cytokines in
patients with prostate cancer. Prostate
2000; 44: 271±4.
100 Blay JY, Burdin N, Rousset F, et al.
Serum interleukin-10 in non-Hodgkin's
lymphoma: a prognostic factor. Blood
1993; 82: 2169±74.
101 Stasi R, Zinzani L, Galieni P, et al.
Detection of soluble interleukin-2 receptor
and interleukin-10 in the serum
of patients with aggressive non-Hodgkin's
lymphoma. Identification of a subset
at high risk of treatment failure.
Cancer 1994; 74: 1792±800.
102 Cortes JE, Talpaz M, Cabanillas F,
Seymour JF, Kurzrock R. Serum levels
of interleukin-10 in patients with
diffuse large cell lymphoma: lack of correlation
with prognosis. Blood 1995; 85:
2516±20.
103 Cortes J, Kurzrock R. Interleukin-10
in non-Hodgkin's lymphoma. Leuk
Lymph. 1997; 26: 251±9.
104 Sarris AH, Kliche KO, Pethambaram
P, et al. Interleukin-10 levels are
often elevated in serum of adults with
Hodgkin's disease and are associated
with inferior failure-free survival. Ann
Oncol 1999; 10: 433±40.
105 Bohlen H, Kessler M, Sextro M,
Diehl V, Tesch H. Poor clinical outcome
of patients with Hodgkin's disease
and elevated interleukin-10 serum
levels. Clinical significance of interleu-
References
kin-10 serum levels for Hodgkin's disease.
Ann Hematol 2000; 79: 110±3.
106 Vassilakopoulos TP, Nadali G, Angelopoulou
MK, et al. Serum interleukin-10
levels are an independent prognostic
factor for patients with Hodgkin's
lymphoma. Haematologica 2001;
86: 274±81.
107 Fayad L, Keating MJ, Reuben JM, et al.
Interleukin-6 and interleukin-10 levels
in chronic lymphocytic leukemia: correlation
with phenotypic characteristics
and outcome. Blood 2001; 97: 256±63.
108 Dummer W, Becker JC, Schwaaf A,
Leverkus M, Moll T, Brocker EB. Elevated
serum levels of interleukin-10 in
patients with metastatic malignant melanoma.
Melanoma Res 1995; 5: 67±8.
109 Fortis C, Foppoli M, Gianotti L, et al.
Increased interleukin-10 serum levels
in patients with solid tumors. Cancer
Lett 1996; 104: 1±5.
110 Wojciechowska-Lacka A, Matecka-
Nowak M, Adamiak E, Lacki JK, Cerkaska-Gluszak
B. Serum levels of interleukin-10
and interleukin-6 in patients
with lung cancer. Neoplasma
1996; 43: 155±8.
111 De Vita F, Orditura M, Galizia G,
et al. Serum interleukin-10 levels in patients
with advanced gastrointestinal
malignancies. Cancer 1999; 86: 1936±
43.
112 De Vita F, Orditura M, Galizia G,
et al. Serum interleukin-10 levels as a
prognostic factor in advanced nonsmall
cell lung cancer patients. Chest
2000; 117: 365±73.
113 De Vita F, Orditura M, Galizia G,
et al. Serum interleukin-10 is an independent
prognostic factor in advanced
solid tumors. Oncol Rep 2000; 7: 357±
61.
114 Chau GY,Wu CW, Lui WY, et al. Serum
interleukin-10 but not interleukin-6 is
related to clinical outcome in patients
with resectable hepatocellular carcinoma.
Ann Surg 2000; 231: 552±8.
115 Nemunaitis J, Fong T, Shabe P, Martineau
D, Ando D. Comparison of
serum interleukin-10 (IL-10) levels between
normal volunteers and patients
with advanced melanoma. Cancer Invest
2001; 19: 239±47.
173